Clinical Trials

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06846671 2026-03-19

CaDAnCe-302

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06943872 2026-03-19

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07277231 2026-03-18

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

22 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

14 enrolled

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT03523975 2026-03-13

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

28 enrolled

Lymphoma, Mantle-Cell

NCT05963074 2026-03-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

33 enrolled

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02392572 2026-03-12

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

LymphoidMyeloidOther hematologic neoplasm

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03223610 2026-03-12

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07294677 2026-03-04

CAVALRY

104 enrolled

Leukemia, Lymphoma

NCT05091424 2026-03-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

137 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06481228 2026-03-02

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Phase NA Recruiting

82 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06481241 2026-03-02

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Phase NA Recruiting

77 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06522386 2026-03-02

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT04169737 2026-02-24

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06466122 2026-02-19

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

28 enrolled

Burkitt Lymphoma, Recurrence

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

64 enrolled

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-02-04

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Phase EARLY_PHASE1 Recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell

NCT04855695 2026-01-21

Avo In R/R And Previously Untreated MCL

72 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

160 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05657652 2025-12-29

CAV Regimen for R/R Ph- B-ALL

Phase NA Recruiting

36 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

110 enrolled

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07154264 2025-12-24

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05168930 2025-12-05

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

45 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05099471 2025-11-28

VIWA-1

80 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2025-11-05

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

170 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05529069 2025-10-24

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

30 enrolled

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05388006 2025-10-14

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

100 enrolled